JW Pharmaceutical
JW Pharmaceutical operates in the healthcare sector, focusing on the development and distribution of medical products and quasi drugs. The company is recognized as a leading player in the global pharmaceutical market, with a diverse portfolio that includes original medicines and medical supplies such as Livalo, Thrupas, Sigmart, and Actemra. Additionally, JW Pharmaceutical is committed to improving patient care by creating specialized dietary products, including low-protein and low-salt food options for individuals with chronic renal insufficiency. Through its comprehensive range of pharmaceutical and healthcare products, the company aims to meet the evolving needs of patients and healthcare providers.
3 past transactions
ProGen Company
Post in 2025
Progene is a biopharmaceutical development venture that emphasizes research and development, collaborating with leading pharmaceutical companies to advance its projects. The company utilizes a multi-target fusion protein technology platform to discover new drug candidates aimed at treating metabolic diseases, immune disorders, and cancer. Progene's approach incorporates both domestic and international open innovation, allowing it to create inventive drugs while fostering partnerships for joint development and technology transfer. This focus on collaboration and innovative drug development positions Progene for continuous growth in the biopharmaceutical sector.
S&E bio
Venture Round in 2022
S&E Bio is a biopharmaceutical company dedicated to developing cell therapies specifically designed to treat neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles. Its innovative approach targets various conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. By leveraging mesenchymal stem cell-derived therapeutics, S&E Bio aims to provide advanced treatment options for patients suffering from these challenging and often incurable diseases.
Argonaut Therapeutics
Corporate Round in 2018
Argonaut Therapeutics Limited, founded in 2016 and based in Oxford, United Kingdom, specializes in developing epigenetically acting drugs for cancer treatment. The company focuses on targeting abnormal arginine methylation, a modification linked to cancer progression, by utilizing pioneering research from the University of Oxford. Argonaut aims to create precision cancer medicines that reprogram cancer cells to trigger the body's natural cell death processes. This innovative approach seeks to provide advanced treatment options that may enhance patient recovery and improve outcomes in cancer therapy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.